

## Special Issue

# Cellular Immune Responses to Infectious Diseases

### Message from the Guest Editor

Since the start of the COVID-19 pandemic, research on immune responses against infectious diseases has attracted significant interest. Additionally, it is now widely accepted that a successful vaccine against infections need not only offer protective humoral immune responses mediated by B cells but also effective cellular immune responses mediated by T cells. Therefore, we are launching this Special Issue on “Cellular Immune Responses to Infectious Diseases” in *Vaccines* to publish recent findings on cellular immune responses against pathogens, such as viruses, bacteria, fungi, and parasites. Implications on vaccine development are highly welcome but not necessary. Acceptable formats include research articles, review articles, and case reports. The research areas of submitted manuscripts may include but are not limited to the following: development of new vaccines against infectious diseases, general T cell responses against pathogens, T cell responses after vaccination, T cell responses in mucosa, interaction between T cells and other immune cells in infections, development of immunological assays related to vaccine development.

---

### Guest Editor

Dr. Jianxuan Wu

Department of Virology, Gilead Sciences, Foster City, CA 94404, USA

---

### Deadline for manuscript submissions

closed (31 July 2024)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/151633](https://mdpi.com/si/151633)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).